Trending...
- Timbrana Helps General Contractors Improve Jobsite Visibility and Subcontractor Accountability
- Everything Policy Unveils Their Classroom Resources Behind Every Policy Topic
- Creole101 Launches Multilingual Dictionary App with 50,000+ Entries, Vocabulary Games and Haitian Cultural Resources
PITTSBURGH, July 25, 2024 ~ PANTHERx Rare, one of the leading rare disease specialty pharmacies in the nation, has announced the appointment of Bansi Nagji as their new CEO effective August 1, 2024. Mr. Nagji, who has been serving as a member of the company's board of directors, will now take on the additional responsibility of leading PANTHERx Rare as its CEO. This change in leadership comes as Rob Snyder, the current co-founder and CEO, transitions to a full-time role as Executive Chair.
With over 25 years of experience in various leadership roles within the healthcare industry, Mr. Nagji brings a wealth of knowledge and expertise to his new position. He has a strong background in pharma services and supply chain management, healthcare technology, and digital platforms. Throughout his career, he has successfully led high-growth businesses and implemented effective strategies for organic and inorganic growth. Prior to joining PANTHERx Rare as Executive Chair in December 2023, Mr. Nagji served as President of Healthcare at GoodRx Inc., as well as Executive Vice President and Chief Strategy and Business Development Officer at McKesson Corporation. He also has extensive experience serving on the boards of private and public companies such as Change Healthcare, Deloitte, and Parata Systems.
More on The PennZone
Meanwhile, Dr. Snyder's transition to full-time Executive Chair marks a significant milestone for PANTHERx Rare since its founding in 2011. As CEO, he played a crucial role in driving the organization's growth and transformation through various clinical, operational, and business development initiatives that have continued to benefit patients. In his new role as Executive Chair, Dr. Snyder will focus on collaborating with industry partners to ensure that PANTHERx Rare maintains its reputation for providing quality patient access to essential medications.
Expressing his excitement about taking on the role of CEO at PANTHERx Rare, Mr. Nagji said that he was looking forward to leading the company through its next phase of growth. He acknowledged Dr. Snyder's leadership and the significant impact he has had on the organization since its inception. Mr. Nagji also shared his passion for building businesses that help people gain access to critical medications and expressed his eagerness to use his experience to support PANTHERx Rare's mission of helping those living with rare diseases. He also praised the company's patient-centric culture and expressed his desire to continue working closely with Dr. Snyder in his new role as Executive Chair.
More on The PennZone
Dr. Snyder, on the other hand, reflected on PANTHERx Rare's journey so far and their goal of improving every aspect of the patient experience. He expressed his excitement about dedicating his full-time focus to developing innovative access and support services for patients along their health journey. Dr. Snyder also expressed confidence in Mr. Nagji's abilities and was eager to continue working with him as PANTHERx Rare enters its next phase of growth.
These executive appointments are a testament to PANTHERx Rare's commitment to providing expert and empathetic patient care, as well as their strong leadership bench and rapidly growing team of professionals. With Mr. Nagji at the helm, supported by Dr. Snyder in his new role, PANTHERx Rare is poised for continued success in delivering quality care for those living with rare diseases.
With over 25 years of experience in various leadership roles within the healthcare industry, Mr. Nagji brings a wealth of knowledge and expertise to his new position. He has a strong background in pharma services and supply chain management, healthcare technology, and digital platforms. Throughout his career, he has successfully led high-growth businesses and implemented effective strategies for organic and inorganic growth. Prior to joining PANTHERx Rare as Executive Chair in December 2023, Mr. Nagji served as President of Healthcare at GoodRx Inc., as well as Executive Vice President and Chief Strategy and Business Development Officer at McKesson Corporation. He also has extensive experience serving on the boards of private and public companies such as Change Healthcare, Deloitte, and Parata Systems.
More on The PennZone
- Roots, Rhythm & Joy Invites Neighbors to Find Community Through Music
- New Children's Picture Book "Adam's Apple" Celebrates Childhood Curiosity and the Funny Misundersta
- Stand Strong Fencing of Hatfield Turns Every October Project Into a Cancer Donation
- New Children's Picture Book "Tippy Tay" Explores the Dangers of Peer Pressure and the Importance of
- Former Goddard Enterprises Managing Director Anthony Ali Joins STS Capital Partners as Managing Director and Partner
Meanwhile, Dr. Snyder's transition to full-time Executive Chair marks a significant milestone for PANTHERx Rare since its founding in 2011. As CEO, he played a crucial role in driving the organization's growth and transformation through various clinical, operational, and business development initiatives that have continued to benefit patients. In his new role as Executive Chair, Dr. Snyder will focus on collaborating with industry partners to ensure that PANTHERx Rare maintains its reputation for providing quality patient access to essential medications.
Expressing his excitement about taking on the role of CEO at PANTHERx Rare, Mr. Nagji said that he was looking forward to leading the company through its next phase of growth. He acknowledged Dr. Snyder's leadership and the significant impact he has had on the organization since its inception. Mr. Nagji also shared his passion for building businesses that help people gain access to critical medications and expressed his eagerness to use his experience to support PANTHERx Rare's mission of helping those living with rare diseases. He also praised the company's patient-centric culture and expressed his desire to continue working closely with Dr. Snyder in his new role as Executive Chair.
More on The PennZone
- Heritage at Manalapan Announces Limited-Time Mortgage Rate Buydown on Select Quick Move-In Homes
- Good Organics Now at Pop Up Grocer NYC With October 30 Sampling Event
- KeysCaribbean Announces Temporarily Reduced Rates At Village at Hawks Cay Villas
- Commercial Manufacturing Validation Completed as November 10 FDA Milestone Approaches; Critical FDA Milestone Close: NRx Pharmaceuticals NAS DAQ: NRXP
- Electives Launches "Electives for Everyone," Making Live Expert-Led Learning Available to Every Employee
Dr. Snyder, on the other hand, reflected on PANTHERx Rare's journey so far and their goal of improving every aspect of the patient experience. He expressed his excitement about dedicating his full-time focus to developing innovative access and support services for patients along their health journey. Dr. Snyder also expressed confidence in Mr. Nagji's abilities and was eager to continue working with him as PANTHERx Rare enters its next phase of growth.
These executive appointments are a testament to PANTHERx Rare's commitment to providing expert and empathetic patient care, as well as their strong leadership bench and rapidly growing team of professionals. With Mr. Nagji at the helm, supported by Dr. Snyder in his new role, PANTHERx Rare is poised for continued success in delivering quality care for those living with rare diseases.
0 Comments
Latest on The PennZone
- Critical FDA Milestone much Closer as Preservative-Free Ketamine Review Advances: NRx Pharmaceuticals (N A S D A Q: NRXP)
- Corner Property Management AAMC Expands Presence with Clover Mill Management Agreement
- Michael Fischer Launches 'Legacy League' Podcast
- Keystone Consulting Engineers Marks Next Chapter of Growth with Refreshed Brand
- AutoProIT Achieves Cyber Essentials Certification, Reinforcing Its Commitment to Secure Digital Transformation
- DayPass llega a ChatGPT y Claude
- DayPass launches in ChatGPT and Claude
- Renkeer Water Quality Sensors Support Efficient Operation of AI Liquid Cooling Systems
- Victor Archibong Expands ItsArchiDuh Creator Brand
- Talented Learning Unveils 2026 LMS Award Winners
- Pittsburgh Digital Marketing Agency Moves to Babcock Boulevard in the North Hills
- ClearSight Therapeutics Receives U.S. Patent Notice of Allowance
- Revinate launches hospitality's first data activation platform
- HLN Consulting Names Lilly Kan as Its First Chief Executive Officer
- BitTitan Accelerates Large-Scale Document Migrations with MigrationWiz
- Clearnetworx Deploys netElastic vBNG, CGNAT And netVision To Power Fiber Expansion Across Colorado's Western Slope
- Glenn Strange - Iconic Horror actor of Universal Studios Frankenstein's Monster Fame Honored
- Creole101 Launches Multilingual Dictionary App with 50,000+ Entries, Vocabulary Games and Haitian Cultural Resources
- Hilton Waikiki Beach Resort & Spa Introduces Level 37 Sky Lounge by Casamigos
- Self-Published Dad's Santa Book Finally Found After 3 Years on Amazon